Rethinking capital – Alternative funding models for biotech | скачать в хорошем качестве

Rethinking capital – Alternative funding models for biotech |

Rethinking capital – Alternative funding models for biotech at Investment Summit, Advanced Therapies Week 2026 Key takeaways 🔷 How alternative financing models are giving biotech companies new ways to fund progress at every stage of development 🔷 The role of structured liquidity in strengthening syndicate alignment, supporting long-term investors and enabling continued scientific execution 🔷 How bespoke funding structures can create stability 🔷 How family offices, angel investors and strategic private investors are bringing longer-term, values-based perspectives into biotech financing 🔷 Practical approaches for leadership teams to evaluate capital options that drive innovation, retain control and accelerate timelines Chairperson Michael E. Meyers (Vice Chairman & Head of M&A and Strategic Advisory Services | H.C. Wainwright & Co., LLC) Speakers Eric Shiozaki (Partner | Revelation Partners) Shyam Patel (Associate Vice President Preclinical Development | CIRM) Vinny Jindal (Chief Executive Officer | Secretome Therapeutucs) Josh House (Managing Director | HealthCare Royalty) Brad Sitko (Chief Investment Officer | XOMA Royalty)